Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in stemi patients: A randomized clinical study

Clinical Therapeutics

Volumn 35, Issue 3, 2013, Pages 261-272

  Liu, Hui Liang ^a   Yang, Yong ^a   Yang, Sheng Li ^a   Luo, Jian Ping ^a   Li, Hong ^a   Jing, Li Min ^a   Shen, Zhi Qi ^a  

^a GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

Atorvastatin; BNP; Hs CRP; Loading dose; MMP 9; STEMI

Indexed keywords

ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GELATINASE B;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLOATING; CONTROLLED STUDY; DEMOGRAPHY; EMERGENCY TREATMENT; FEMALE; FOLLOW UP; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HEART PERFORMANCE; HUMAN; INFLAMMATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; C-REACTIVE PROTEIN; COMBINED MODALITY THERAPY; ECHOCARDIOGRAPHY; FEMALE; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PYRROLES; VENTRICULAR FUNCTION, LEFT;

EID: 84874997758     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.01.009     Document Type: Article

References (38)

1. Burke A.P., Tracy R.P., Kolodgie F., et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002, 105:2019-2023.
2. Kazemi-Bajestani S.M., Ghayour-Mobarhan M., Ebrahimi M., et al. C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease. Clin Lab 2007, 53:49-56.
3. Sabatine M.S., Morrow D.A., Jablonski K.A., et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007, 115:1528-1536.
4. Bonnet J., McPherson R., Tedgui A., et al. Comparative effects of 10-mg versus 80-mg atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 2008, 30:2298-2313.
5. Zebrack J.S., Anderson J.L., Maycock C.A., et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002, 89:145-149.
6. Hoffmann R., Suliman H., Haager P., et al. Association of C-reactive protein and myocardial perfusion in patients with ST-elevation acute myocardial infarction. Atherosclerosis 2006, 186:177-183.
7. Fazlinezhad A., Rezaeian M.K., Yousefzadeh H., et al. Plasma brain natriuretic peptide (BNP) as an indicator of left ventricular function, early outcome and mechanical complications after acute myocardial infarction. Clin Med Insights Cardiol 2011, 5:77-83.
8. Yu X.Y., Liu C.Z., Wang J.H., et al. Brain natriuretic peptide and left ventricular remodeling after emergency percutaneous coronary intervention in acute myocardial infarction patients [article in Chinese]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2008, 20:204-206.
9. Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13-20.
10. Mihatov S. Thrombolysis or percutaneous coronary intervention in acute myocardial infarct [article in Croatian]. Acta Med Croatica 2004, 58:139-142.
11. Cucherat M., Bonnefoy E., Tremeau G. WITHDRAWN: primary angioplasty versus intravenous thrombolysis for acute myocardial infarction. Cochrane Database Syst Rev 2007, (3). CD001560.
12. Tanaka A., Kawarabayashi T., Nishibori Y., et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation 2002, 105:2148-2152.
13. Maekawa Y., Asakura Y., Anzai T., et al. Relation of stent overexpansion to the angiographic no-reflow phenomenon in intravascular ultrasound-guided stent implantation for acute myocardial infarction. Heart Vessels 2005, 20:13-18.
14. Katayama T., Kubo N., Takagi Y., et al. Relation of atherothrombosis burden and volume detected by intravascular ultrasound to angiographic no-reflow phenomenon during stent implantation in patients with acute myocardial infarction. Am J Cardiol 2006, 97:301-304.
15. Nakamura T., Kubo N., Ako J., et al. Angiographic no-reflow phenomenon and plaque characteristics by virtual histology intravascular ultrasound in patients with acute myocardial infarction. J Interv Cardiol 2007, 20:335-339.
16. Kirma C., Izgi A., Dundar C., et al. Clinical and procedural predictors of no-reflow phenomenon after primary percutaneous coronary interventions: experience at a single center. Circ J 2008, 72:716-721.
17. Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007, 49:1272-1278.
18. Briguori C., Visconti G., Focaccio A., et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009, 54:2157-2163.
19. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res 1997, 35:2-3. World Medical Association Declaration of Helsinki.
20. Switula D. Principles of good clinical practice (GCP) in clinical research. Sci Eng Ethics 2000, 6:71-77.
21. Kushner F.G., Hand M., Smith S.C., et al. 2009 Focused updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 120:2271-2306.
22. Dorobantu M., Fruntelata A.G., Scafa-Udriste A., et al. B-type natriuretic peptide (BNP) and left ventricular (LV) function in patients with ST-segment elevation myocardial infarction (STEMI). Maedica (Buchar) 2010, 5:243-249.
23. Abulhul E., McDonald K., Martos R., et al. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Clin Ther 2012, 34:91-100.
24. Riesen W.F., Engler H., Risch M., et al. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 2002, 23:794-799.
25. Verma S., Li S.H., Badiwala M.V., et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002, 105:1890-1896.
26. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
27. Szmitko P.E., Wang C.H., Weisel R.D., et al. New markers of inflammation and endothelial cell activation: part I. Circulation 2003, 108:1917-1923.
28. Bell R.M., Yellon D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003, 41:508-515.
29. Samson R.H., Nair D.G. Influence and critique of the JUPITER trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein). Semin Vasc Surg 2011, 24:172-179.
30. Gratsianskii N.A. Statin is indicated to all patients with high risk of complications of coronary heart disease irrespective of the level of low density lipoprotein cholesterol. Results of HPS [in Russian]. Kardiologiia 2002, 42:84-85.
31. Schmidt R., Bultmann A., Fischel S., et al. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Circ Res 2008, 102:302-309.
32. Yu D.Q., Lin S.G., Chen J.Y., et al. Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome. Arch Med Sci 2011, 7:433-439.
33. Thunyakitpisal P.D., Chaisuparat R. Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci 2004, 94:403-409.
34. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998, 18:1671-1678.
35. Funayama H., Ishikawa S.E., Kubo N., et al. Increases in interleukin-6 and matrix metalloproteinase-9 in the infarct-related coronary artery of acute myocardial infarction. Circ J 2004, 68:451-454.
36. Munagala V.K., Burnett J.C., Redfield M.M. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004, 29:707-769.
37. Magga J., Vuolteenaho O., Tokola H., et al. Involvement of transcriptional and posttranscriptional mechanisms in cardiac overload-induced increase of B-type natriuretic peptide gene expression. Circ Res 1997, 81:694-702.
38. Hara H., Nakamura M., Yokouchi I., et al. Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: America study. Ther Adv Cardiovasc Dis 2009, 3:357-365.